Experience
Classen Immunotherapies, Inc.
Elan Pharmaceuticals, Inc.
Defending Elan at district court and in two appeals with respect to Classen’s infringement allegations regarding Elan’s Skelaxin® portfolio. District court granted summary judgment of non-infringement in favor of Elan. Federal Circuit affirmed, and Supreme Court denied cert. Also successfully represented Elan in related reexamination proceedings before the U.S. Patent and Trademark Office (USPTO).
Classen Immunotherapies, Inc. v. Elan Pharmaceuticals, Inc., 1:04-cv-03521, D. Md., Judges Bennett, Quarles, Sullivan
Classen Immunotherapies, Inc. v. Elan Pharmaceuticals, Inc., 14-1671, Fed. Cir., Judges Prost, Lourie, Gilstrap
Classen Immunotherapies, Inc. v. Elan Pharmaceuticals, Inc., 17-1033, Fed. Cir., Judges Prost, Lourie, Taranto
Elan Pharmaceuticals, Inc. v. Eon Labs, Inc.
Elan Pharmaceuticals, Inc.
Elan Pharmaceuticals, Inc. v. Ivax Pharmaceuticals, Inc.
Elan Pharmaceuticals, Inc.
Placeware, Inc.
Under Armour, Inc. v. Skechers U.S.A., Inc.
Under Armour, Inc.
Under Armour, Inc. v. Salt Armour, Inc.
Under Armour, Inc.
Under Armour, Inc. v. Energy Armor, Inc.
Under Armour, Inc.
Cognate Bioservices, Inc. v. Alan Smith Consulting Inc.
MacroCure, Ltd.
GlaxoSmithKline v. Synthon Pharmaceuticals, Inc.
GlaxoSmithKline
Apotex Inc. v. Senju Pharmaceutical
Senju Pharmaceuticals Co. Ltd.
Due to international data regulations, we’ve updated our privacy policy. Click here to read our privacy policy in full.
We use cookies on this website to provide you with the best user experience. By accepting cookies, you agree to our use of cookies. Please note that if you opt not to accept or if you disable cookies, the “Your Finnegan” feature on this website will be disabled as well. For more information on how we use cookies, please see our Privacy Policy.
Finnegan is thrilled to announce the launch of our new blog, Ad Law Buzz, devoted solely to breaking news, developments, trends, and analysis in advertising law.